SAVA

Cassava Sciences

Halal Rating :
To Be Determined
Last Price $2.48 Last updated:
Market Cap $1.38b
7D Change -2.75%
1 Year Change -89.38%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NASDAQ
Next Earnings Date Nov. 11, 2024

Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing new therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. Their lead therapeutic candidate is simufilam, an investigational drug designed to treat Alzheimer's disease. The company is currently conducting Phase 3 clinical trials of simufilam.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio

Company Impact

Help us evaluate Cassava Sciences's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates